Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7407-7414
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7407
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Kaplan-Meier survival curves. A: Recurrence-free survival (RFS) and B: Overall survival (OS) based on human epidermal growth factor 2 (HER2) expression in stage II-III gastric cancer patients. HR: Hazard ratio.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Kaplan-Meier survival curves. Overall survival (OS) based on human epidermal growth factor receptor 2 (HER2) expression in A: Stage II and B: Stage III gastric cancer patients. HR: Hazard ratio; CI: Confidence interval.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Kaplan-Meier survival curve. Overall survival (OS) based on human epidermal growth factor receptor 2 (HER2) expression in stage II and III gastric cancer patients who received adjuvant chemotherapy. A: Total patients both stage II and III; B: Divided by each stage. HR: Hazard ratio; CI: Confidence interval.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Kaplan-Meier survival curve. Recurrence free survival (RFS) based on human epidermal growth factor receptor 2 (HER2) expression in stage II and III gastric cancer patients who did not receive adjuvant chemotherapy. HR: Hazard ratio; CI: Confidence interval.